Essential hypertension
Conditions
Interventions
experimental group :granules of Huanglianjiedu decoction
The control group:Valsartan capsule
Sponsors
Affiliated Hospital of Shandong University of TCM
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria of Western medicine for essential hypertension and vertigo with hyperactivity of liver fire syndrome; Hypertension is grade 1, and the patients diagnosed as primary hypertension (grade 1) with hyperactivity of liver fire syndrome after the intervention of standard lifestyle; 2. Patients with stable blood pressure in the past two weeks who have not been treated with traditional Chinese medicine or proprietary Chinese medicine, or have been treated with western medicine but whose blood pressure is still at grade 1 of hypertension; 3. Between 18 and 75 years old, gender is not limited; 4. Patients who voluntarily participated in the trial and signed the informed consent and cooperated with various investigations and tests.
Exclusion criteria
Exclusion criteria: 1. Patients with secondary hypertension, stubborn hypertension, malignant hypertension, acute and subacute hypertension, white coat hypertension and unstable blood pressure; 2. Pregnant and lactating women, as well as women of childbearing age who do not agree to take contraceptive measures during the trial; 3. Patients with mental disorders and poor cooperation; 4. The patients with serious heart disease, severe neurosis and heart, liver and kidney dysfunction were confirmed by examination; 5. patients with severe endocrine, hematopoietic system, liver, kidney and other primary diseases, malignant tumor and psychosis; 6. Patients with uncorrected hyperthyroidism and hypothyroidism; patients with nephrotic syndrome, diabetes mellitus and acute hepatobiliary diseases; 7. Patients with severe cerebrovascular accident, heart disease, severe trauma, major operation and other primary diseases with general instability and poor prognosis within 6 months; 8. Patients who have other diseases, are under medication and affect the observation of test drug; 9. Patients who have participated in clinical trials of other drugs within three months; 10. Other conditions that the researchers think are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean dynamic blood pressure;symptom score of TCM;Ventricular brachial artery blood pressure;Quality of life score;FOS,IL6,MAPK8;BMI;Blood sugar;Total cholesterol;LDL-C;HDL-C;ALT?AST;BUN?Cr;Routine urine;Routine stool;ecg; | — |
Countries
China
Contacts
Public ContactJiao Huachen
Affiliated Hospital of Shandong University of TCM
Outcome results
None listed